Description
Spesolimab is indicated for the treatment of generalized pustular psoriasis flares in adults.
The most common adverse reactions include fatigue, nausea and vomiting, headache, pruritus (itching) and prurigo (itchy bumps), bruising, and urinary tract infection.
It was approved for medical use in the United States in September 2022, and in European Union in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
SPEVIGO (spesolimab-sbzo) injection, for intravenous use Initial U.S. Approval: 2022
See full prescribing information : Click Here
Get Access To Spevigo (spesolimab-sbzo) Injection In India On Request
Brand Name “Spevigo” or Generic Name “spesolimab-sbzo” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or you can call at 9891296838 or WhatsApp at 9891296838
